|
Eric Sievers joined Seattle Genetics in July 2006. He is responsible for directing, planning and executing clinical development activities of several of the company’s therapeutic programs. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics supervising the oncology development of interleukin-21 and Atacicept. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for over a decade. His academic research focused on improving treatment outcomes for patients with acute myeloid leukemia by defining the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) and evaluating novel flow cytometric techniques to predict leukemic recurrence. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research and is certified by the American Board of Pediatrics.
| 